GlaxoSmithKline has submitted a BLA to the FDA for Cervarix (human papillomavirus vaccine, AS04 adjuvant-adsorbed), its cervical cancer vaccine. If licensed, the vaccine will be indicated for the prevention of cervical cancer and precancerous lesions associated with the most common cancer-causing human papillomavirus types. The proprietary adjuvant system called AS04 is intended to enhance immune response and increase duration of protection. The BLA includes data from clinical trials that i...